Regeneron Pharmaceuticals ... Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of China for HS-20094 (a dual GLP-1/GIP receptor agonist ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced an in-licensing agreement with Hansoh Pharmaceuticals to acquire clinical ... provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist.

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

The acquisition of HS-20094 enhances Regeneron’s portfolio of obesity and metabolic programs, which aim to improve the quality of weight loss and address long-term health comorbidities.

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline ... This novel therapeutic candidate (HS-20094) – studied in over 1,000 patients and administered ...